New evidence that microRNA bone biomarkers can improve early diagnosis of osteoporosis
We would like to draw your attention to our lastest publication: “Cost-utility analysis of fracture risk assessment using microRNA compared with Standard Tools and no Monitoring in the Austrian female Population.” Bone. Volume 108, 2018; Pages 44-54. This study presents the first comprehensive attempt to model the cost-effectiveness of circulating microRNAs for bone fracture risk assessment in a central European female post-menopausal population in comparison to DXA and FRAX®. The results demonstrate that the osteomiR™ test can be a cost-effective alternative to established risk assessment strategies. Click here to read the study